Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003223), on September 04, 2025, and is solely responsible for the information contained therein.